Compare Msci Inc (MSCI) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Msci Inc vs TransMedics Group Inc — how do they compare? Msci Inc trades at $554.53 (market cap $40.32B), while TransMedics Group Inc trades at $86.5 (market cap $3.00B). The key difference: Msci Inc is far larger — about 13.4× TransMedics Group Inc's market cap, and Msci Inc pays a 1.48% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| MSCI | TMDX | |
|---|---|---|
Market Cap | $40.32B | $3.00B |
Sector | Financials | Technology |
52-Week High | $643.83 | $150.42 |
52-Week Low | $511.84 | $61.99 |
Enterprise Value | $46.48B | $3.39B |
Dividend Yield | 1.48% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSCI trades at $551.39, down 3.77% over 24 hours, amid a bearish technical signal. The stock shows strong fundamentals with revenue growth to $3.13B in 2025 and a net income margin of 40.73%, though it faces a high P/E of 30.32. Recent developments include the acquisition of First Street and a strategic partnership with UBS, enhancing its private markets platform. Cash flow turned positive in 2025, but high debt levels and a negative equity position pose risks.
The outlook is mixed: analyst consensus is bullish with a $728.14 price target, but technical indicators signal caution. Upside potential hinges on continued earnings beats and revenue growth, while risks include market volatility and execution challenges. Investors should weigh strong profitability against valuation concerns and debt load.
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings performance. The company reported strong 2025 results with $605M revenue and 31.4% net margin, though 2026 projections show margin compression. Recent news highlights growth initiatives in kidney transplantation and European markets, alongside ongoing legal investigations into fiduciary duties.
The stock offers upside to the $99.57 consensus price target, supported by analyst bullishness (69% buy ratings), but faces risks from margin pressure, legal scrutiny, and earnings misses. Revenue growth remains a key catalyst, though execution risks and investor sentiment headwinds warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
